Background: In many randomized controlled trials, patients and doctors are more interested in the per-protocol effect than in the intention-to-treat effect. However, valid estimation of the per-protocol effect generally requires adjustment for prognostic factors associated with adherence. These adherence adjustments have been strongly questioned in the clinical trials community, especially after 1980 when the Coronary Drug Project team found that adherers to placebo had lower 5-year mortality than non-adherers to placebo. Methods: We replicated the original Coronary Drug Project findings from 1980 and re-analyzed the Coronary Drug Project data using technical and conceptual developments that have become established since 1980. Specifically, we used logistic models for binary outcomes, decoupled the definition of adherence from loss to follow-up, and adjusted for pre-randomization covariates via standardization and for post-randomization covariates via inverse probability weighting. Results: The original Coronary Drug Project analysis reported a difference in 5-year mortality between adherers and non-adherers in the placebo arm of 9.4 percentage points. Using modern approaches, we found that this difference was reduced to 2.5 (95% confidence interval: 22.1 to 7.0). Conclusion: Valid estimation of per-protocol effects may be possible in randomized clinical trials when analysts use appropriate methods to adjust for post-randomization variables.
Clinical decision-making relies heavily on the findings of randomized clinical trials. Because substantial societal resources are allocated to the conduct of these studies, it is surprising that randomized trial findings are often summarized by a single measure that provides incomplete clinical information: the intention-to-treat effect. In an intention-to-treat analysis, individuals are assigned to the treatment arm they were randomized to, regardless of whether they actually took the treatment as intended in the study's protocol. In placebocontrolled trials, patients assigned to treatment may stop taking it and those assigned to placebo may start taking treatment. As a result, the intention-to-treat effect may be closer to the null than the effect that would have been found if all patients had taken their assigned study treatment exactly as specified by the study protocol, that is, the per-protocol effect or the effect under full adherence to the protocol.
The intention-to-treat effect has well-known advantages. 1 However, patients and their doctors may be more interested in the per-protocol effect than in the intention-to-treat effect when making treatment decisions. 2 In trials that try to detect harm, a closer-to-thenull-by-design intention-to-treat effect is misleading and generally discouraged. In the increasingly frequent pragmatic trials, the benefits of randomization may be overwhelmed by serious deviations from protocol, including lack of adherence to the assigned interventions and loss to follow-up. Therefore, in many randomized trials, intention-to-treat analyses need to be complemented with properly conducted per-protocol analyses that adjust for incomplete adherence. 3 However, there is no universally accepted method to estimate per-protocol effects. The naı¨ve approach commonly referred to as ''per-protocol analysis'' (i.e. comparing only individuals who adhere to their assigned treatment while they adhere to it) is hardly a contender for a valid estimation of the per-protocol effect because this approach would only be valid if non-adherence occurred essentially at random. 2 Adjustment for prerandomization variables will generally help reduce bias in naı¨ve per-protocol analyses, but such adjustment is not common in practice. In fact, most clinical trial protocols devote little, if any, attention to the estimation of the per-protocol effect.
Some of this lack of interest can be traced back to an influential article published in 1980 in the New England Journal of Medicine. 4 This article had a chilling effect on subsequent attempts to conduct per-protocol analyses: investigators from the Coronary Drug Project (CDP) demonstrated that, among individuals assigned to placebo, the 5-year mortality risk was higher among those who did not adhere than among those who did adhere to the placebo pills. This finding is taught in courses around the world and often quoted as a reminder of the dangers of analyses that deviate from the intention-to-treat principle.
Because placebo cannot affect mortality, the difference between compliers and noncompliers in the CDP clearly indicates that adherence is a marker of good prognosis and that a comparison of adherers and nonadherers is inherently biased. That statistical adjustment, using the best methods available at that time, could not eliminate the bias was interpreted as an indication that analyses to estimate the per-protocol effect were to be distrusted, if not outright discouraged.
In the 35 years since the publication of the CDP paper, new statistical methods have been developed to adjust for protocol deviations. 5, 6 These methods can validly incorporate pre-and post-randomization variables; therefore, they will generally result in less biased per-protocol effect estimates than those obtained from naı¨ve per-protocol analyses. Randomized trials that, like the CDP, compare sustained interventions over long periods are the best candidates to benefit from these new methods, which estimate more robust perprotocol effect estimates, to complement the usual intention-to-treat analyses.
Here we (1) revisit the CDP findings in light of technical and conceptual developments that have become established since 1980 and (2) review the options available for the estimation of per-protocol effects today. We start by summarizing the CDP and its findings.
A brief summary of the CDP

Design and conduct of the CDP
The CDP was a six-arm double-blind placebo-controlled randomized clinical trial designed to identify treatments that would reduce premature mortality in men with a history of myocardial infarction (MI). 7, 8 The study was funded by the National Heart, Lung, and Blood Institute of the US National Institutes of Health (NIH). Enrollment occurred between March 1966 and October 1969, and follow-up continued until late 1974 to early 1975. The trial compared five active treatments to placebo: clofibrate (ethyl chlorophenoxyisobutyrate, 1.8 mg/day), low-dose equine estrogen (2.5 mg/day), high-dose equine estrogen (5.0 mg/day), dextrothyroxine (6 mg/day), and nicotinic acid (3 mg/day). Increased risk of adverse events was observed in the high-and low-dose estrogen arms and the dextrothyroxine arm; these arms were discontinued in 1970, 1973, and 1971, respectively. 9 Men were eligible to participate if they were aged between 30 and 64 years at the time of randomization, had an electrocardiogram (ECG) with documented MI at least 3 months before entry, a New York Heart Association functional class I (no limitation of physical activity) or II (slight limitation), no previous surgery for coronary artery disease, no other life-limiting diseases or conditions that could affect long-term followup, no contraindication for the study drugs, willingness to participate and to adhere to study drugs as assessed by a 2-month control period, and no anti-coagulant therapy, lipid influencing drugs, or insulin use at baseline. Men were excluded if evidence suggested MI due to coronary artery embolism, aortic dissection, or prolonged arrhythmia.
Randomization was within each of 53 study centers and by risk group, with low risk defined as having had only one previous MI and no associated complications, and high risk as having had more than one MI or one MI with complications. Figure 1 displays an overview of the study timeline. Three initial monthly visits were conducted to determine eligibility and to estimate adherence to placebo; randomization occurred at the third visit, and dosage was adjusted at two additional monthly visits. Patients were prescribed three pills daily at randomization and dosage was increased by up to three pills per visit, on the basis of drug tolerance, to a final dose of nine daily pills by the fifth visit. Follow-up visits were planned to occur every 4 months until study completion, dropout, or death. 7 Up to three close-out visits were planned after study completion to assess any impact of drug withdrawal. Three of the study arms (both estrogen arms and the dextrothyroxine arm) were discontinued during follow-up because of adverse events. [10] [11] [12] 
Clofibrate versus placebo: published results in 1980
A total of 1103 patients were randomized to the clofibrate arm and 2789 to the placebo arm. 9 Minimum follow-up duration for surviving participants was 54 months; 96% were followed up for at least 5 years and 63% for at least 6 years. As of 31 August 1974, 7.4% of survivors in the clofibrate arm and 8.0% of those in the placebo arm had stopped attending study visits and were classified as lost to follow-up. At 56-60 months, 5.5% of the clofibrate arm and 4.2% of the placebo arm were receiving less than 20% of the prescribed dose (p = 0.28), and 11.5% of the clofibrate arm and 9.4% of the placebo arm were receiving \80% of the prescribed dose (p = 0.20). Mean adherence to the maximum study dose was 77.1% in the clofibrate arm and 77.8% in the placebo arm; median adherence was 86.1% for clofibrate and 87.1% for placebo. 9 The percentage of patients with adherence of \80% by the end of follow-up was 5.5% in the clofibrate arm and 9.4% in the placebo arm. 9 The 5-year all-cause mortality was 20.0% in the clofibrate arm and 20.9% in the placebo arm (p = 0.55). The 5-year incidence for the secondary combined outcome of death due to coronary heart disease or occurrence of definite non-fatal MI was 23.8% for clofibrate and 26.2% for placebo (p = 0.13). Adjustment for baseline characteristics did not materially alter the study results. 9 The CDP Research Group concluded that there was no evidence that clofibrate reduced 5year mortality. 9 How the CDP convinced us that adjustment for non-adherence is futile
In 1980, the CDP investigators also compared the 5year mortality risk between adherers and non-adherers within each arm. To calculate adherence, the clinic staff computed the percentage of capsules prescribed that were actually taken by the patient during the previous 4 months. This assessment was made by questioning the patient and/or counting the capsules returned at each visit. Adherence was categorized into one of five levels: 80%-100%, 60%-79%, 40%-59%, 20%-39%, and less than 20% adherence to prescribed dosage. Adherence was standardized by prescribed dosage, and the cumulative adherence was computed from this value until death or the end of year 5. Finally, cumulative adherence was dichotomized at \80% versus 80% over the follow-up. 4 In the placebo arm, 882 participants had a cumulative adherence of \80% (noncompliers) and 1813 participants had a cumulative adherence of 80% (compliers) until death or end of follow-up. Among noncompliers, 28% died within the first 5 years of follow-up, compared with only 15% of compliers; a difference of over 13%. After adjustment for 40 baseline characteristics, the difference in 5-year mortality risk was still about 10%. The authors concluded that compliers and noncompliers must be different in ways not accounted for by the available data because a greater adherence to placebo is not expected to have a causal effect on the mortality risk. This inability to adjust for adherence in the placebo arm strongly suggests that any attempt at an adherence-adjusted analysis of the entire trial data would be futile. By extension, if adherence adjustment was not successful in the CDP, a large trial with extensive and detailed data collection at baseline and over time, why should we expect it to be successful in any other randomized trial?
An early 21st century update of the CDP placebo comparisons
The approaches to data analysis that were standard in 1980 would not necessarily be the primary choice today. A modern comparison of compliers and noncompliers Figure 1 . Study timeline, Coronary Drug Project. Timing of study visits and variable measurement. L t is the vector of postrandomization covariates measured at visit t and A t is an indicator for adherence level for the period from t to just before t + 1 measured at visit t + 1. A 0 is measured at follow-up visit 1 (FV1) or, for individuals who died or dropped out before FV1, at IV4 and IV5.
in the placebo arm of the CDP would differ from the 1980 analysis.
We conducted a re-analysis of the placebo arm of the CDP to estimate the difference in 5-year mortality risk under adherence levels of \80% versus 80%. Because placebo should have no effect on the 5-year mortality risk, a non-null estimate would suggest that compliers and noncompliers are indeed irreconcilably different. On the other hand, a null estimate would increase confidence in our ability to sufficiently adjust for the differences between compliers and noncompliers when estimating the per-protocol effect.
Our re-analysis differs from the original 1980 analysis in three aspects: definition of adherence during missed visits, adjustment for baseline predictors of adherence, and adjustment for post-randomization predictors of adherence. We proposed four updates to the 1980 analysis.
Definition of adherence
When a participant missed a study visit, his adherence to the placebo pills was unknown and therefore needed to be imputed. The 1980 analysis set adherence to 0% at missed visits, even though individuals may have partly adhered to placebo during the period preceding the missed visit. Because individuals were more likely to miss visits when they were about to die (mortality hazard ratio for those who did versus did not miss the previous visit was 1.8; 95% confidence interval (CI): 1.3-2.6), setting adherence to 0% may artificially increase the proportion of noncompliers among patients at high risk of death.
We updated the analysis by decoupling the classification of an individual as a noncomplier from his risk of death in the near future. To do so, we used past adherence history as an indicator of expected adherence by setting adherence at missed visits equal to adherence at the most recently attended visit, which may better reflect an individual's expected adherence. We censored individuals who missed more than three consecutive adherence measurements (see the Supplementary Appendix for details).
Adjustment for pre-randomization risk factors
To adjust for baseline factors, the 1980 analysis used linear regression to model the 5-year mortality risk as a function of the baseline covariates, which were then evaluated at their average values in the study population. That was a typical choice at the time. We updated the analysis to a logistic regression model followed by standardization by the baseline covariates.
Adjustment for post-randomization risk factors
Because adherence varies over time, an analysis adjusted for only baseline variables may miss important prognostic factors that impacted adherence during the follow-up but that were not present at the time of randomization. The use of this post-baseline information will generally improve adherence-adjusted analyses. Indeed, not adjusting for post-randomization variables makes the extreme assumption that, conditional on the baseline variables, adherence is independent of all measured and unmeasured post-randomization variables. The 1980 analysis, however, could not adjust for any post-baseline, time-varying covariates because no methods had yet been developed for this purpose at the time. As a result, the CDP investigators could not take advantage of much of the data so carefully collected over the course of the study.
We updated the analysis using inverse probability weighting 6 to adjust for post-randomization risk factors. Because the weight assigned to an individual at time t is a function of the individual's risk factor and adherence history through t, the analysis adjusts for post-randomization variables that are joint determinants of adherence and the outcome. This analysis makes the less extreme assumption that adherence was independent of the unmeasured but not the measured post-randomization variables. If all such variables were correctly measured and modeled, 6,13 the inverse probability weighted analysis would allow us to validly estimate the 5-year mortality that would have been observed in this trial if everyone in the placebo arm had adhered at least 80% to placebo compared with if no one in the placebo arm had adhered at least 80% (see the Supplementary Appendix for more details).
Sensitivity analyses
We performed a variety of sensitivity analyses for dealing with missing adherence, including setting adherence to the cumulative average adherence up to each missed visit, setting adherence to 0% or 80% for up to two missed visits and then censoring, and setting adherence to half of the most recent available adherence value, with and without censoring. We also varied the definition of adherence by including or ignoring information about prescribed dosage and changing the cut-point for dichotomous adherence to 70% and 90%. Finally, we included weights for censoring due to dropout and permuted the covariates to assess the potential for over-fitting. Full results of the sensitivity analyses are provided in the Supplementary Appendix.
Revisiting the CDP placebo comparisons
The CDP data tapes in the NIH data repository were corrupted in the 1990s and the data were irretrievable. Fortunately, Dr Paul Canner, principal statistician of the CDP, had preserved a version of the de-identified data sets, which we used for our analyses. In collaboration with Dr Canner, we will make the data sets user friendly. We will then submit the data sets and their documentation to the NIH data repository.
Replication of the 1980 CDP findings
As a check of the integrity of the data, we first replicated the main tables and results of the 1980 CDP article. 4 To do so, we mimicked the methods described in the article as closely as possible (see Supplementary Appendix for a detailed description).
Of 2630 individuals with non-missing values of the baseline covariates, 68.8% had a cumulative average adherence to placebo of at least 80%. We found a difference in 5-year mortality risk of 14.3 percentage points in the unadjusted analysis and of 10.9% after adjustment for baseline covariates. These estimates are within 1.5 percentage points of the estimates reported in the original 1980 analysis (unadjusted difference = 13.1%; adjusted difference = 9.4%). These small discrepancies are explained by the need to recalculate percent adherence and cumulative average adherence because of corruption in the original variables and to correct some errors in coding for adherence at baseline and time of death. A similar analysis conducted in the clofibrate arm also showed a slight increase in 5-year mortality in the non-adherers compared to the original 1980 estimates (Table 1) .
A 2015 re-analysis of the CDP As described above, our updated analysis differs from the original CDP analysis in three aspects: (1) handling of adherence at missed visits, (2) type of regression model for adjustment using baseline predictors, and (3) adjustment for post-randomization predictors of adherence using inverse probability weighting. Changing the handling of adherence at missed visits reduced our sample size by 217 individuals. These individuals missed more than three consecutive visits and were censored.
Adherence of \80% was associated with low prior adherence; acute coronary insufficiency, intermittent cerebral ischemic attack, congestive heart failure, and angina; recent use of diuretics and anti-arrhythmic agents; and smoking (Supplementary Table A2 ). The adherence weights, truncated at their 99th percentile to prevent undue influence of outliers, had a mean of 1.01 (standard deviation (SD) = 0.51) and a range of 0.02-3.94. Table 2 shows the estimated difference in 5-year mortality risk between noncompliers and compliers in the placebo arm of the CDP, both in our replication of the 1980 analysis and in our updated analysis. The unadjusted difference in 5-year mortality risk (95% CI) was 11.0 percentage points (6.5-15.6). The difference in 5-year mortality risk was 7.0 percentage points (2.7-11.2) after adjustment for baseline covariates. Our handling of adherence and the use of logistic regression resulted in a 2.4 percentage point reduction compared with the CDP analysis that set missing adherence to 0 and used linear regression. The difference in 5-year mortality risk was 2.5 percentage points (22.1 to 7.0) after further adjustment for post-randomization covariates.
That is, after adjustment, there was little survival difference between compliers and noncompliers in the placebo arm. This finding was robust to many possible variations of the analysis, which we explored in multiple sensitivity analyses (see Supplementary Appendix) .
Where does this leave us when estimating per-protocol effects?
The above shows that an analysis of the CDP that tries to adjust for adherence is not necessarily doomed. Our finding weakens the arguments against adherenceadjusted analyses of randomized trials for estimating the per-protocol effect. The question remains of how to better estimate such effect.
Each of the two broad approaches to the estimation of per-protocol effects-instrumental variable estimation and direct adjustment for measured covariateshas shortcomings. Adjustment for noncompliance via instrumental variable estimation 14 is desirable because it removes the need to collect data on prognostic factors that predict compliance. For example, Holme et al. 15 recently used instrumental variable estimation to estimate the per-protocol effect of once-only sigmoidoscopy on colon cancer and overall mortality rate in a large randomized trial conducted in Norway. However, instrumental variable estimation requires strong assumptions in trials with interventions that, unlike a baseline sigmoidoscopy, need to be sustained during the follow-up. The use of instrumental variable estimations is even more questionable if the interventions are unmasked and potentially available to individuals in all arms (not a concern for the CDP). Direct adjustment for measured covariates is another approach for per-protocol analyses of randomized trials of sustained interventions. Typically, these analyses require adjustment for pre-and post-randomization prognostic factors that predict adherence. Appropriate adjustment for post-randomization factors requires methods specifically designed for that purpose. These methods, collectively referred as g-methods and developed by Robins 13, 16 , include inverse probability weighting, which we used in our updated analysis of the CDP.
The key limitation of direct adjustment is the possibility of residual bias if the set of adjustment variables fails to include important joint predictors of adherence to the protocol and the outcome of interest (note that when the analysis fails to adjust for important joint predictors of both loss to follow-up and of the outcome of interest, then intention-to-treat effect estimates may also be biased because of informative censoring). 17 In fact, there are examples, other than the CDP, in which adherers and non-adherers are so different with respect to their risk of developing the outcome that the available data are insufficient for direct statistical adjustment. For example, Holme et al. 15 demonstrated that the mortality rate was greater in participants who refused to undergo a sigmoidoscopy compared with those who did undergo sigmoidoscopy, even after adjustment for multiple factors. However, the adjustment variables did not include cigarette smoking and other important prognostic factors, which had they been available for inclusion might have explained some of the observed differences in mortality rate.
Many randomized trials collect only limited data after randomization, which prevents valid estimation of per-protocol effects when instrumental variable estimation is not possible. Even in randomized trials that collect abundant baseline and post-randomization data, adjusted per-protocol effect estimates are not routinely presented along with intention-to-treat effect estimates. Appropriately adjusted per-protocol effect estimates can provide better estimates of both the efficacy of a treatment and the harms associated with the treatment in randomized trials. The omission of appropriately adjusted perprotocol effect estimates is especially problematic in randomized trials that assess potential harm and in those in which little effort is made to encourage adherence to the protocol, such as pragmatic and large simple trials. 18 The lack of established methodologic standards for adjusted per-protocol estimates contributes to the problem because it creates uncertainty among investigators and sponsors who need to justify their analytic choices to journal editors and regulators. 19 
Conclusion
Widely held beliefs about the impossibility of conducting adherence-adjusted analyses may be partly based on weak empirical evidence and out-of-date methodology. Per-protocol effects can be validly estimated in clinical trials when sufficient data are available and appropriate adjustment methods are used. Supplementing intentionto-treat analyses with per-protocol effect estimates can Table 2 . Comparison of original and updated estimates for the placebo arm, Coronary Drug Project.
Five-year mortality risk difference, % (95% CI)
Unadjusted
Adjusted for baseline variables a via linear regression Adjusted for 39 baseline variables: age, race, risk group, number of prior MIs, relative body weight, medical history, prescriptions of non-study medications, lab findings, blood pressure, cardiomegaly, ECG findings, cigarette smoking, and physical activity level (see Supplementary Table A1 for details). b The original 1980 analysis did not include logistic regression; we include it here for comparison purposes. c Adjusted for the 39 baseline variables (age, race, risk group, prior MIs, and relative body weight were baseline only) and 34 post-randomization variables: medical history, prescriptions of non-study medications, lab findings, blood pressure, cardiomegaly, ECG findings, cigarette smoking, and physical activity level (see Supplementary Table A1 for details). Comparing individuals with \80% versus 80% at each visit.
allow richer, more nuanced inference from clinical trials. Clinical research would benefit from a concerted effort to establish clear guidelines for the definition and estimation of per-protocol effects.
